Sapna Syngal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/233163/publications.pdf

Version: 2024-02-01

85 papers	8,574 citations	94433 37 h-index	56724 83 g-index
87 all docs	87 docs citations	87 times ranked	9044 citing authors

#	Article	IF	Citations
1	Adaptation and early implementation of the PREdiction model for gene mutations (PREMM5â„¢) for lynch syndrome risk assessment in a diverse population. Familial Cancer, 2022, 21, 167-180.	1.9	7
2	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 2022, 162, 772-785.e4.	1.3	60
3	Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. British Journal of Cancer, 2022, , .	6.4	2
4	Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access. Genetics in Medicine, 2022, 24, 1196-1205.	2.4	6
5	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2022, 117, 846-864.	0.4	11
6	Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2022, 95, 1025-1047.	1.0	6
7	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2022, 162, 2063-2085.	1.3	35
8	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology, 2022, 40, 3257-3266.	1.6	69
9	Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals. Familial Cancer, 2021, 20, 111-116.	1.9	5
10	Letter to the Editor-Recent advances in Lynch syndrome: response to MÃ¸ller et al.. Familial Cancer, 2021, 20, 121-122.	1.9	0
11	Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. JCO Oncology Practice, 2021, 17, e236-e247.	2.9	22
12	Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs). JCO Precision Oncology, 2021, 5, 808-816.	3.0	7
13	Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome. Gastroenterology, 2021, 161, 143-150.e4.	1.3	11
14	COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Pancreatology, 2021, 21, 1048-1051.	1.1	8
15	Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prevention Research, 2021, 14, 215-222.	1.5	26
16	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	1.5	15
17	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?â€”Letter. Cancer Prevention Research, 2021, 14, 973-974.	1.5	3
18	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	48

#	Article	IF	Citations
19	Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 830-837.e1.	4.4	38
20	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
21	Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm₅ Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. Journal of Clinical Oncology, 2020, 38, 4086-4094.	1.6	7
22	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 92, 997-1015.e1.	1.0	35
23	Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. New England Journal of Medicine, 2020, 383, 1028-1039.	27.0	43
24	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 159, 1916-1934.e2.	1.3	68
25	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 1751-1767.	0.4	22
26	A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors. Cancer Prevention Research, 2020, 13, 291-298.	1.5	12
27	Endoscopic Removal of Colorectal Lesions: Recommendations by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 435-464.	0.4	88
28	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 415-434.	0.4	103
29	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 91, 463-485.e5.	1.0	163
30	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 158, 1131-1153.e5.	1.3	228
31	Spotlight: US Multi-Society Task Force on Colorectal Cancer Recommendations for Follow-up After Colonoscopy and Polypectomy. Gastroenterology, 2020, 158, 1154.	1.3	23
32	Endoscopic Removal of Colorectal Lesionsâ€"Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 158, 1095-1129.	1.3	187
33	Spotlight: US Multi-Society Task Force on Colorectal Cancer Recommendations for Endoscopic Removal of Colorectal Lesions. Gastroenterology, 2020, 158, 1130.	1.3	3
34	Endoscopic Removal of Colorectal Lesionsâ€"Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 91, 486-519.	1.0	95
35	Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 193-199.	2.5	11
36	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 2019, 21, 213-223.	2.4	151

#	Article	IF	Citations
37	Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nature Genetics, 2019, 51, 1308-1314.	21.4	47
38	Recent advances in Lynch syndrome. Familial Cancer, 2019, 18, 211-219.	1.9	70
39	A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. PLoS Genetics, 2019, 15, e1008344.	3.5	13
40	Health behaviours and beliefs in individuals with familial pancreatic cancer. Familial Cancer, 2019, 18, 457-464.	1.9	4
41	Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Familial Cancer, 2019, 18, 317-325.	1.9	6
42	Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. Psycho-Oncology, 2018, 27, 1711-1718.	2.3	13
43	Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 49-58.	4.4	25
44	Intercepting Pancreatic Cancer. Pancreas, 2018, 47, 1175-1176.	1.1	1
45	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	1.6	383
46	Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Familial Cancer, 2017, 16, 377-387.	1.9	11
47	Biallelic Mismatch Repair Deficiency: Management and Prevention of a Devastating Manifestation of the Lynch Syndrome. Gastroenterology, 2017, 152, 1254-1257.	1.3	7
48	Comparison of Colonoscopy Quality Measures Across Various Practice Settings and the Impact of Performance Scorecards. Digestive Diseases and Sciences, 2017, 62, 894-902.	2.3	13
49	Development and Validation of the PREMM₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. Journal of Clinical Oncology, 2017, 35, 2165-2172.	1.6	126
50	Reply to M.S. Daniels et al. Journal of Clinical Oncology, 2017, 35, 2588-2589.	1.6	0
51	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	2.5	29
52	Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A stateâ€ofâ€theâ€science review. Cancer, 2016, 122, 2633-2645.	4.1	131
53	Association of a let-7 miRNA binding region ofTGFBR1with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis, 2016, 37, 751-758.	2.8	16
54	A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointestinal Endoscopy, 2016, 84, 115-125.e4.	1.0	30

#	Article	IF	Citations
55	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
56	ReCAP: Oncologistsâ€™ Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 259-260.	2.5	3
57	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	29
58	Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genetics in Medicine, 2016, 18, 152-161.	2.4	36
59	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
60	Patient experiences living with pancreatic cancer risk. Hereditary Cancer in Clinical Practice, 2015, 13, 13.	1.5	14
61	Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology, 2015, 149, 604-613.e20.	1.3	225
62	ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. American Journal of Gastroenterology, 2015, 110, 223-262.	0.4	1,204
63	Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genetics in Medicine, 2015, 17, 815-821.	2.4	21
64	Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer, 2015, 121, 3281-3289.	4.1	30
65	Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study. Gastrointestinal Endoscopy, 2015, 82, 812-818.	1.0	43
66	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	1.6	603
67	Colorectal Cancer in Young Adults. Digestive Diseases and Sciences, 2015, 60, 722-733.	2.3	90
68	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genetics in Medicine, 2015, 17, 569-577.	2.4	231
69	Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2014, 80, 197-220.	1.0	48
70	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1159-1179.	0.4	363
71	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastroenterology, 2014, 147, 502-526.	1.3	397
72	Therapy-Associated Polyposis as a Late Sequela of CancerÂTreatment. Clinical Gastroenterology and Hepatology, 2014, 12, 1046-1050.	4.4	11

#	Article	IF	Citations
73	Comparison of the clinical prediction model PREMM_{1,2,6}and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut, 2013, 62, 272-279.	12.1	49
74	ATM Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	9.4	442
75	Prevalence and Phenotypes of APC and MUTYH Mutations in Patients With Multiple Colorectal Adenomas. JAMA - Journal of the American Medical Association, 2012, 308, 485-492.	7.4	183
76	Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology, 2012, 142, 796-804.	1.3	570
77	The PREMM1,2,6 Model Predicts Risk of MLH1, MSH2, and MSH6 Germline Mutations Based on Cancer History. Gastroenterology, 2011, 140, 73-81.e5.	1.3	171
78	Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population. Cancer Prevention Research, 2011, 4, 9-22.	1.5	153
79	Inherited Colorectal Cancer Syndromes. Cancer Journal (Sudbury, Mass), 2011, 17, 405-415.	2.0	100
80	Sharing Genetic Test Results in Lynch Syndrome: Communication With Close and Distant Relatives. Clinical Gastroenterology and Hepatology, 2008, 6, 333-338.	4.4	104
81	Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1469.	7.4	160
82	Surveillance of patients at high risk for colorectal cancer. Medical Clinics of North America, 2005, 89, 61-84.	2.5	12
83	Phenotypic Characteristics Associated With the <EMPH TYPE="ITAL">APC</EMPH> Gene I1307K Mutation in Ashkenazi Jewish Patients With Colorectal Polyps. JAMA - Journal of the American Medical Association, 2000, 284, 857.	7.4	29
84	Potential roles of genetic biomarkers in colorectal cancer chemoprevention. Journal of Cellular Biochemistry, 2000, 77, 28-34.	2.6	11
85	Hereditary Nonpolyposis Colorectal Cancer: A Call for Attention. Journal of Clinical Oncology, 2000, 18, 2189-2192.	1.6	9